Overview
This 2-day conference is the third of its kind. It will provide an update on the current status for biosimilars in EU and internationally with focus on both regulatory and scientific challenges as well as market access and experiences. Patients' and physicians' approach to use of biosimilars will be part of the scope including a discussion on biosimilars adoption into current treatment guidelines in EU. The conference will consist of plenary lectures followed by interactive panel discussions providing participants an opportunity to bring forward their own experience and share their thoughts and ideas with the experts.
Program Committee
-
Steffen Thirstrup, MD, PhD Chief Medical Officer
European Medicines Agency, Netherlands -
Sabine Atzor, MPharm, RPh Head of EU Regulatory Policies
F. Hoffmann-La Roche Ltd, Switzerland -
Suzette Kox, MPharm Senior Director International-Biosimilars Medicines Group
Medicines for Europe, Belgium -
Elena Wolff-Holz, MD, PhD Chair, Biosimilar Medicinal Products Working Party (BMWP) of CHMP; Assessor
Paul-Ehrlich Institut, Germany -
Christian Schneider, DrMed Head of Biopharma Excellence and Chief Medical Officer (Biopharma)
PharmaLex, Denmark
Have an account?